Financial Performance - The total operating revenue for the reporting period is expected to be ¥424,302,528.44, representing a year-on-year increase of 2.08%[6] - The net profit attributable to shareholders is expected to be ¥84,027,314.36, a decrease of 1.89% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be ¥73,998,665.02, down 0.69% year-on-year[6] - The basic earnings per share is expected to be ¥0.58, a decline of 1.69% from the previous year[6] Assets and Equity - The total assets at the end of the reporting period are expected to be ¥972,370,429.72, an increase of 5.57% year-on-year[6] - The equity attributable to shareholders is expected to be ¥834,860,594.74, up 6.79% compared to the beginning of the period[6] - The net asset per share attributable to shareholders is expected to be ¥5.74, reflecting a year-on-year increase of 7.69%[6] Market Strategy - The company has focused on market demand, adjusting product structure and production control dynamically, and accelerating the market introduction of new products such as Celecoxib capsules and Oseltamivir phosphate capsules[7] Cautionary Notes - The company warns that the financial data presented is preliminary and has not been audited, urging investors to be cautious[8] - The final data will be disclosed in the official 2025 annual report, which will supersede the preliminary figures[8]
梓橦宫(920566) - 2025 Q4 - 年度业绩